{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:21:16Z","timestamp":1768634476454,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy, radiotherapy, and other advanced therapeutics, including rituximab or immune checkpoint inhibitors, have improved the prognosis in recent decades, there are still a number of patients with relapsed or refractory\u00a0(R\/R) lymphoma with a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy has provided a curative option for patients with relapsed or refractory lymphoma. Numerous clinical trials have been conducted worldwide and presented inspiring results that give insight into this breakthrough therapy. The development of cancer cell therapy in China has been rapid in the past years and dominates the field with the USA. This review aims to summarize the published results of CAR T-cell therapy alone or in combination with other therapies in mainland China, both in R\/R NHL and R\/R HL.<\/jats:p>","DOI":"10.1007\/s12094-023-03153-1","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T10:01:57Z","timestamp":1681639317000},"page":"2793-2800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent advances in CAR T-cell therapy for lymphoma in China"],"prefix":"10.1007","volume":"25","author":[{"given":"Yuxuan","family":"Che","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-6411","authenticated-orcid":false,"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,16]]},"reference":[{"key":"3153_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2017.04.024","volume":"401","author":"W Chen","year":"2017","unstructured":"Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63\u201371.","journal-title":"Cancer Lett"},{"issue":"3","key":"3153_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","volume":"10","author":"RL Elstrom","year":"2010","unstructured":"Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymph Myeloma Leuk. 2010;10(3):192\u20136.","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"2","key":"3153_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transpl. 2017;52(2):216\u201321.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"3153_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"25","key":"3153_CR5","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced hodgkin\u2019s lymphoma. N Engl J Med. 2016;374(25):2419\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"3153_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267\u201376.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3153_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"1","key":"3153_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"LA Johnson","year":"2017","unstructured":"Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38\u201358.","journal-title":"Cell Res"},{"issue":"1","key":"3153_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","volume":"3","author":"M Sadelain","year":"2003","unstructured":"Sadelain M, Rivi\u00e8re I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35\u201345.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3153_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","volume":"3","author":"WY Ho","year":"2003","unstructured":"Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003;3(5):431\u20137.","journal-title":"Cancer Cell"},{"issue":"26","key":"3153_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"26","key":"3153_CR12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"3153_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"3153_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112(5):1570\u201380.","journal-title":"Blood"},{"issue":"6","key":"3153_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3153_CR16","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-duration complete remissions of diffuse large B Cell lymphoma after Anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245\u201353.","journal-title":"Mol Ther"},{"issue":"4","key":"3153_CR17","first-page":"276","volume":"40","author":"X Xiao","year":"2019","unstructured":"Xiao X, Jiang YY, Cao YQ, Li Q, Jin X, Meng JX, et al. Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2019;40(4):276\u201380.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"3153_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01888-z","author":"Z Ying","year":"2022","unstructured":"Ying Z, Xie Y, Zheng W, Liu W, Lin N, Tu M, et al. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma: 2-year results of a phase 1 trial. Bone Marrow Transpl. 2022. https:\/\/doi.org\/10.1038\/s41409-022-01888-z.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"3153_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.3686","volume":"10","author":"Z Ying","year":"2021","unstructured":"Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China. Cancer Med. 2021;10(3):999\u20131011.","journal-title":"Cancer Med"},{"issue":"10","key":"3153_CR20","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286","volume":"2","author":"LB John","year":"2013","unstructured":"John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2(10): e26286.","journal-title":"Oncoimmunology"},{"key":"3153_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma. Front Oncol. 2019;9:767.","journal-title":"Front Oncol"},{"issue":"6","key":"3153_CR22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353.","journal-title":"Nat Med"},{"issue":"1","key":"3153_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"3153_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood. 2020;135(1):17\u201327.","journal-title":"Blood"},{"issue":"3","key":"3153_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jcyt.2020.01.008","volume":"22","author":"C Zeng","year":"2020","unstructured":"Zeng C, Cheng J, Li T, Huang J, Li C, Jiang L, et al. Efficacy and toxicity for CD22\/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020;22(3):166\u201371.","journal-title":"Cytotherapy"},{"issue":"9","key":"3153_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","volume":"9","author":"G Wei","year":"2021","unstructured":"Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, et al. CD19\/CD22 Dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study. Cancer Immunol Res. 2021;9(9):1061\u201370.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"3153_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","volume":"155","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155(2):160\u201375.","journal-title":"Clin Immunol"},{"key":"3153_CR28","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","volume":"1","author":"WY Zhang","year":"2016","unstructured":"Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Trans Target Ther. 2016;1:16002.","journal-title":"Signal Trans Target Ther"},{"key":"3153_CR29","doi-asserted-by":"publisher","first-page":"17054","DOI":"10.1038\/sigtrans.2017.54","volume":"2","author":"WY Zhang","year":"2017","unstructured":"Zhang WY, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, et al. Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Trans Target Ther. 2017;2:17054.","journal-title":"Signal Trans Target Ther"},{"issue":"10","key":"3153_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"14","key":"3153_CR31","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344.","journal-title":"Blood"},{"issue":"1","key":"3153_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang Y, Liu Y, Tong C, Wang C, Guo Y, et al. Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial. Leukemia. 2022;36(1):189\u201396.","journal-title":"Leukemia"},{"key":"3153_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/ejh.13080","volume":"101","author":"E Grignano","year":"2018","unstructured":"Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM. The role of radiotherapy as salvage and\/or consolidation treatment in relapsed\/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018;101:150\u20139.","journal-title":"Eur J Haematol"},{"issue":"1","key":"3153_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","volume":"43","author":"C Qu","year":"2020","unstructured":"Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q, et al. Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden. J Immunother. 2020;43(1):32\u20137.","journal-title":"J Immunother"},{"issue":"2","key":"3153_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3153_CR36","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood.V77.10.2292.2292","volume":"77","author":"A Lohri","year":"1991","unstructured":"Lohri A, Barnett M, Fairey RN, O\u2019Reilly SE, Phillips GL, Reece D, et al. Outcome of treatment of first relapse of Hodgkin\u2019s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77(10):2292\u20138.","journal-title":"Blood"},{"issue":"2","key":"3153_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/clim.1998.4636","volume":"90","author":"R Chiarle","year":"1999","unstructured":"Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90(2):157\u201364.","journal-title":"Clin Immunol"},{"issue":"6","key":"3153_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1006\/smim.1998.0156","volume":"10","author":"R Horie","year":"1998","unstructured":"Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457\u201370.","journal-title":"Semin Immunol"},{"issue":"5878","key":"3153_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/299065a0","volume":"299","author":"U Schwab","year":"1982","unstructured":"Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin\u2019s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65\u20137.","journal-title":"Nature"},{"issue":"5","key":"3153_CR40","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin Lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3153_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","volume":"10","author":"D Wang","year":"2020","unstructured":"Wang D, Zeng C, Xu B, Xu JH, Wang J, Jiang LJ, et al. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30(+) lymphoma patients. Blood Cancer J. 2020;10(1):8.","journal-title":"Blood Cancer J"},{"issue":"6382","key":"3153_CR42","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03153-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03153-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03153-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:19:49Z","timestamp":1693214389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03153-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,16]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03153-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,16]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}